Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

In BRAF(V600mut) metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Louveau, Baptiste, Jouenne, Fanelie, Reger de Moura, Coralie, Sadoux, Aurelie, Baroudjian, Barouyr, Delyon, Julie, Herms, Florian, De Masson, Adele, Da Meda, Laetitia, Battistella, Maxime, Dumaz, Nicolas, Lebbe, Celeste, Mourah, Samia
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721518/
https://ncbi.nlm.nih.gov/pubmed/31426590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11081203
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller